Joint development of’Piribastat’ with French Quantum Genomics
Anticipation of the emergence of a new mechanism of resistant hypertension treatment
Dong Wha Pharm announced on the 1st that it has signed an exclusive license agreement for the development and sales of’Pirivastat’, a drug for resistant hypertension of French Quantum Genomics.
‘Resistant hypertension’, which does not stabilize blood pressure even with three or more treatments, including diuretics, accounts for 10-20% of all hypertensive patients.
Dong Wha Pharm said, “Pirivastat, which is being developed with the aim of FDA approval, will contribute to prolonging the patient’s life expectancy by presenting a new treatment option for patients with resistant hypertension without an appropriate treatment.”
According to Dong Wha Pharm, Pirivastat is currently undergoing a phase 3 clinical trial in patients with resistant hypertension in the United States, Europe, and South America. It is known that additional global phase 3 clinical trials, including Korean patients, will begin within this year. The results of global phase 2 clinical trials in patients with heart failure will be announced next year.
Dong Wha Pharm not only develops and commercializes Pirivastat exclusively in Korea, but also participates in global clinical research.
Yoo Jun-ha, CEO of Donghwa Pharm, said, “With this contract, we have an opportunity to develop a treatment for resistant hypertension and heart failure. With this contract, we will focus on securing a new drug pipeline through active open innovation.”
Quantum Genomics is a French drug developer.
Jean-Philippe Milon, CEO of Quantum Genomics, said, “We are happy to develop Dongwha Pharm. and Pirivastat.” I think it’s a partner of “.
Pirivastat is a new drug candidate in the brain aminopeptidase A inhibitor (BAPAI) family. It inhibits the production of angiotensin III in the brain’s renin-angiotensin system (Brain RAS), thereby reducing blood pressure, diuresis, and resistance to the triple action of heart rate regulation. It is being developed as a treatment for hypertension and heart failure.
Copyright holder © The Unauthorized Reproduction and Redistribution of the Medical Hyeopsis is prohibited.